<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Influenza vaccination in persons with egg allergy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Influenza vaccination in persons with egg allergy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Influenza vaccination in persons with egg allergy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John M Kelso, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julie Wang, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott H Sicherer, MD, FAAAAI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of the intramuscular inactivated influenza vaccines (IIVs) and the intranasal live-attenuated influenza vaccine (LAIV) are cultured on fluid from chicken embryos. As a result, there is a small amount of egg protein in these vaccines. Thus, there is a theoretical risk of inducing an allergic reaction when administering the influenza vaccine to a person with hen's egg (HE) allergy. However, many of these same patients are also at higher risk of an adverse outcome due to influenza infection (eg, age less than two years, history of asthma) and would therefore benefit from vaccination.
        </p>
        <p>
         This topic reviews the risks and benefits of administration of the influenza vaccine in patients with HE allergy. Other issues related to HE allergy (including prevalence) and allergic reactions to vaccines are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2409.html" rel="external">
          "Egg allergy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
         The measles, mumps, and rubella (MMR) vaccine is not contraindicated in patients with HE allergy. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines", section on 'Measles, mumps, and rubella'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2390.html" rel="external">
          "Egg allergy: Management", section on 'Avoidance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28638413">
         <span class="h1">
          RISKS ASSOCIATED WITH INFLUENZA INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both seasonal and pandemic influenza infection can lead to severe infection and death, particularly in certain high-risk groups. Seasonal influenza results in higher mortality rates among patients with certain chronic medical conditions (eg, asthma), pregnant females, and those at the extremes of age. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">
          "Seasonal influenza and pregnancy", section on 'Effects on pregnancy'
         </a>
         .)
        </p>
        <p>
         Influenza vaccination is recommended for all individuals six months of age and older and is particularly important in those at increased risk of complications. (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          RISK OF ANAPHYLAXIS TO VACCINES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic reactions to a vaccine may be caused by the immunizing agent itself or to other proteins/haptens that are introduced into the vaccine during the production process. These may include residual animal proteins, antibiotics, preservatives, stabilizers, virus-inactivating compounds, and latex [
         <a href="#rid1">
          1
         </a>
         ]. Thus, episodes of anaphylaxis caused by the influenza vaccine may be due to components other than egg.
        </p>
        <p>
         As an example, there were 12 adverse events consistent with possible anaphylaxis after administration of an egg-free influenza vaccine (Flublok) that were reported between January 16, 2013 and July 31, 2014 through the Vaccine Adverse Event Reporting System (VAERS) in the United States [
         <a href="#rid2">
          2
         </a>
         ]. These reactions occurred in adults with self-reported hen's egg (HE) allergy or a previous allergic reaction to
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         (IIV). Had these patients received an egg-containing vaccine, their reactions may have been erroneously attributed to egg.
        </p>
        <p>
         In another example, a particular brand of influenza vaccine used in Japan during the 2011 to 2012 season was associated with a high rate of anaphylaxis. These patients had elevated levels of immunoglobulin E (IgE) against the immunizing agent (hemagglutinin) compared with controls with and without HE allergy [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
         Overall, anaphylaxis induced by influenza vaccine is a rare event [
         <a href="#rid4">
          4-7
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A survey of children and adolescents enrolled at four health maintenance organizations from 1991 to 1997 revealed no episodes of anaphylaxis to influenza vaccine out of 197,964 doses administered during this time period [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A survey of children and adults enrolled at nine health maintenance organizations from 2009 to 2011 revealed 10 episodes of anaphylaxis to influenza vaccine out of 7,434,628 doses given alone during this time period for a rate of 1.35 per million doses [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of confirmed anaphylaxis to two versions of H1N1 pandemic vaccines was approximately 2 per million doses administered (97 cases) [
         <a href="#rid5">
          5
         </a>
         ]. Insufficient information was available to confirm anaphylaxis in an additional 117 cases. Anaphylaxis was excluded in 181 cases of reported anaphylaxis to the vaccines. The rate of anaphylaxis was within the range expected for vaccines in general (1 to 10 per million doses of vaccine).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several cases of anaphylaxis to the intranasal influenza vaccine have been reported, although these cases were not directly linked to HE allergy [
         <a href="#rid6">
          6
         </a>
         ]. No studies have directly compared the rate of anaphylactic reactions between the intranasal live-attenuated vaccine and the injectable inactivated vaccine. It is not possible to compare the two forms of the influenza vaccine with regard to the risk of anaphylaxis, because it is such a rare event.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Fatal anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A review of reports to the VAERS over a 15-year period from 1990 to 2005, during which 747 million doses of influenza vaccine were administered in the United States, revealed four reports of death shortly after influenza vaccination that identified anaphylaxis as the cause [
         <a href="#rid8">
          8
         </a>
         ]. No information on HE allergy was provided nor was any evaluation performed to determine whether these were allergic reactions.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          VACCINE EGG PROTEIN CONTENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, influenza vaccine manufacturers did not state the egg protein content of the vaccines. Now, most manufacturers of these vaccines provide this information in the package inserts.
        </p>
        <p>
         The vaccine ovalbumin content is typically expressed in micrograms per 0.5 mL dose. All of the vaccines are reported to contain ≤1 mcg per 0.5 mL dose.
        </p>
        <p>
         Independent investigators assayed several brands and lots of the 2009 to 2010 seasonal and H1N1 influenza vaccines and found that the actual ovalbumin content of the vaccines was one or two orders of magnitude lower than the manufacturers' claimed maximum levels [
         <a href="#rid9">
          9,10
         </a>
         ]. All lots tested of the seasonal influenza vaccines approved for use in the United States for 2010 to 2011 contained less than 0.17 mcg of ovalbumin per 0.5 mL dose [
         <a href="#rid11">
          11
         </a>
         ], although it is possible that untested lots had higher levels.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SAFETY OF VACCINES IN PATIENTS WITH EGG ALLERGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Safe administration of injectable influenza vaccine (containing up to 0.7 mcg ovalbumin per 0.5 mL dose) to over 4000 individuals with hen's egg (HE) allergy has been reported [
         <a href="#rid12">
          12-21
         </a>
         ]. These studies included more than 500 patients with a history of anaphylaxis to egg ingestion who were vaccinated with trivalent
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         (IIV), all without serious reactions.
        </p>
        <p>
         Safe administration of the intranasal live-attenuated influenza vaccine (LAIV) containing &lt;0.24 mcg ovalbumin per 0.2 mL dose has been demonstrated in over 1000 patients with HE allergy [
         <a href="#rid22">
          22-24
         </a>
         ]. Of these patients, 39 percent had a history of anaphylaxis to egg, and 63 percent had a diagnosis of asthma or recurrent wheezing. No acute systemic allergic reactions were reported.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          ALTERNATIVE METHODS OF VACCINE PRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most influenza vaccines are produced in fluid from embryonated eggs. Alternative methods of influenza virus propagation have been developed, including a cell culture-based vaccine (Flucelvax) and a recombinant vaccine (Flublok), although there is no preference for the use of these vaccines in hen's egg (HE) allergic recipients, because egg-based vaccines are not associated with any increased risk, and allergic reactions to egg-free vaccines are still possible [
         <a href="#rid25">
          25-32
         </a>
         ]. (See
         <a class="local">
          'Risk of anaphylaxis to vaccines'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          APPROACH TO EVALUATION AND VACCINE ADMINISTRATION
         </span>
        </p>
        <p class="headingAnchor" id="H50073519">
         <span class="h2">
          Risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin testing (prick or intradermal) with influenza vaccine prior to administration is no longer recommended for patients with hen's egg (HE) allergy [
         <a href="#rid1">
          1,33,34
         </a>
         ]. In studies of patients with HE allergy, the presence of a positive skin test to influenza vaccine was not predictive of a subsequent reaction. Skin testing with the vaccine is still appropriate when evaluating a patient with a history of a reaction to the influenza vaccine itself as opposed to a history of reaction to egg. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H50073599">
         <span class="h2">
          Vaccine choice
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of vaccine depends upon the age of the patient, as well as comorbidities and risk factors for severe or complicated influenza or adverse reactions, but is unrelated to HE allergy status. (See
         <a class="local">
          'Risks associated with influenza infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults", section on 'Choice of vaccine formulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Choice of vaccine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H712082827">
         <span class="h2">
          Professional society recommendations
         </span>
         <span class="headingEndMark">
          —
         </span>
         All US professional society and government guidelines specifically recommend that patients with HE allergy receive any age-appropriate influenza vaccine, including egg-based vaccines [
         <a href="#rid33">
          33-35
         </a>
         ].
        </p>
        <p>
         US allergy guidelines from the American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology (ACAAI) Joint Task Force on Practice Parameters [
         <a href="#rid35">
          35
         </a>
         ] state the following regarding influenza vaccines (both
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         [IIV] and LAIV):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Influenza vaccines should be administered to individuals with egg allergy of any severity, just as they would be to individuals without egg allergy."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "No special precautions beyond those recommended for the administration of any vaccine to any patient are necessary for administration of influenza vaccine to egg-allergic individuals."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Vaccine providers and screening questionnaires do not need to ask about the egg allergy status of recipients of influenza vaccine."
        </p>
        <p>
        </p>
        <p>
         The American Academy of Pediatrics (AAP) Committee on Infectious Diseases, in its Recommendations for Prevention and Control of Influenza in Children, 2020 to 2021 [
         <a href="#rid33">
          33
         </a>
         ], states the following regarding HE allergy and influenza vaccine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "There is strong evidence that egg-allergic individuals can safely receive influenza vaccine without any additional precautions beyond those recommended for any vaccine.‍"
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "The presence of egg allergy in an individual is not a contraindication to receive an IIV or LAIV."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "[Influenza] vaccine recipients with egg allergy are at no greater risk for a systemic allergic reaction than those without egg allergy."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Precautions, such as choice of a particular vaccine, special observation periods, or restriction of administration to particular medical settings, are not warranted and constitute an unnecessary barrier to immunization."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "It is not necessary to inquire about egg allergy before the administration of any influenza vaccine, including on screening forms."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Standard vaccination practice for all vaccines in children should include the ability to respond to rare acute hypersensitivity reactions."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Children who have had a previous allergic reaction to the influenza vaccine should be evaluated by an allergist to determine whether future receipt of the vaccine is appropriate."
        </p>
        <p>
        </p>
        <p>
         The Advisory Committee on Immunization Practices (ACIP) has revised its guidance for the 2023 to 2024 influenza season. The ACIP now also states that egg allergy does not necessitate additional safety measures for influenza vaccination, including with egg-based vaccines, beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg [
         <a href="#rid34">
          34
         </a>
         ]. All vaccines should be administered in settings where personnel and equipment needed for prompt recognition and treatment of acute hypersensitivity reactions are available.
        </p>
        <p>
         We recommend choosing any age-appropriate, approved injectable influenza vaccine  (
         <a class="graphic graphic_table graphicRef79474" href="/z/d/graphic/79474.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef67562" href="/z/d/graphic/67562.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef60449" href="/z/d/graphic/60449.html" rel="external">
          table 3
         </a>
         ) for patients with HE allergy, including those with a history of anaphylaxis to egg.
        </p>
        <p class="headingAnchor" id="H630395">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the administration of influenza vaccine to recipients with HE allergy is based upon observational studies and extensive clinical experience (see
         <a class="local">
          'Safety of vaccines in patients with egg allergy'
         </a>
         above). It is consistent with guidelines from the AAP [
         <a href="#rid33">
          33
         </a>
         ], ACIP [
         <a href="#rid34">
          34
         </a>
         ], and the AAAAI/ACAAI Joint Task Force on Practice Parameters [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         We recommend that all patients ≥6 months of age with HE allergy, including those with a history of anaphylaxis to egg ingestion, receive annual immunization with an influenza vaccine according to the indications for all other patients without HE allergy. (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults", section on 'Whom to vaccinate'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We would administer any age-appropriate, approved influenza vaccine  (
         <a class="graphic graphic_table graphicRef79474" href="/z/d/graphic/79474.html" rel="external">
          table 1
         </a>
         ) in these patients in the usual manner according to the indications and contraindications outlined in the tables  (
         <a class="graphic graphic_table graphicRef67562" href="/z/d/graphic/67562.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef60449" href="/z/d/graphic/60449.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any provider who administers any vaccine to any individual must have the personnel, medications, and resuscitative equipment available to treat potential anaphylaxis [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3522573929">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110758.html" rel="external">
          "Society guideline links: Seasonal influenza vaccination"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Egg protein in influenza vaccines
         </strong>
         – Most intramuscular inactivated influenza vaccines (IIVs) and live-attenuated influenza vaccines (LAIVs) contain a small amount of egg protein. The amount of egg protein in the vaccines has decreased significantly over the years, and all egg-based vaccines now have low ovalbumin levels. No serious reactions have been reported after administration of egg-based LAIV or IIV (containing &lt;0.24 mcg per 0.2 mL dose for LAIV and up to 0.7 mcg ovalbumin per 0.5 mL dose for IIV) in recipients with hen's egg (HE) allergy, including in those with a history of anaphylaxis to egg ingestion. (See
         <a class="local">
          'Vaccine egg protein content'
         </a>
         above and
         <a class="local">
          'Risk of anaphylaxis to vaccines'
         </a>
         above and
         <a class="local">
          'Safety of vaccines in patients with egg allergy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment prior to vaccination
         </strong>
         – Vaccine providers and screening questionnaires do not need to ask about the HE allergy status of recipients of influenza vaccine. Skin testing with influenza vaccine prior to administration in patients with HE allergy is no longer suggested. Skin testing with the vaccine is still appropriate when evaluating a patient with a history of a reaction to the influenza vaccine itself, as opposed to a history of reaction to egg. Patients with a history of an allergic reaction to the influenza vaccine should be referred to an allergy specialist for evaluation. (See
         <a class="local">
          'Risk assessment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Who to vaccinate
         </strong>
         – Many patients with HE allergy are at increased risk of influenza complications, including young children and those with a history of asthma or wheezing, and therefore would benefit from vaccination. We recommend that all patients ≥6 months of age with HE allergy, including those with a history of anaphylaxis to egg ingestion, receive annual immunization with an influenza vaccine according to the indications for all other patients without egg allergy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="local">
          'Approach to evaluation and vaccine administration'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults", section on 'Whom to vaccinate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Which influenza vaccine
         </strong>
         – We would administer any age-appropriate, approved injectable influenza vaccine  (
         <a class="graphic graphic_table graphicRef79474" href="/z/d/graphic/79474.html" rel="external">
          table 1
         </a>
         ) in these patients according to the indications and contraindications outlined in the tables  (
         <a class="graphic graphic_table graphicRef67562" href="/z/d/graphic/67562.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef60449" href="/z/d/graphic/60449.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          How to vaccinate
         </strong>
         – The vaccine is administered in the usual manner (ie, in a single dose rather than in two or more doses as a graded challenge and without a special observation period following the vaccine). (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety precautions
         </strong>
         – Any provider who administers any vaccine to any person should have the personnel, medications, and resuscitative equipment available to treat potential anaphylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic reactions to vaccines
         </strong>
         – Allergic reactions to the influenza vaccine, including anaphylaxis, may still occur, as with any vaccine. These reactions can be caused by the immunizing agent itself or to other proteins/haptens besides egg that are introduced into the vaccine during the production process. Patients with a history of an allergic reaction to the influenza vaccine should be referred to an allergy specialist for evaluation. (See
         <a class="local">
          'Risk of anaphylaxis to vaccines'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo EJ. Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis 2015; 60:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagao M, Fujisawa T, Ihara T, Kino Y. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis. J Allergy Clin Immunol 2016; 137:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavares F, Delaigle A, Slavin D, et al. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine 2011; 29:6402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasu N, Ghaffari G, Craig ET, Craig TJ. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis 2008; 2:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waibel KH, Gomez R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J Allergy Clin Immunol 2010; 125:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JT, Rank MA, Squillace DL, Kita H. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010; 125:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinney KK, Webb L, Petersen M, et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 125:e1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnon R, Primeau MN, Des Roches A, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010; 126:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhawt MJ, Chernin AS, Howe L, et al. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010; 105:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011; 127:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011; 106:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webb L, Petersen M, Boden S, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011; 128:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fung I, Spergel JM. Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis. J Allergy Clin Immunol 2012; 129:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Des Roches A, Paradis L, Gagnon R, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol 2012; 130:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhawt MJ, Spergel JM, Rank MA, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol 2012; 109:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Des Roches A, Samaan K, Graham F, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol Pract 2015; 3:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol 2015; 136:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015; 351:h6291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses 2008; 2:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev Vaccines 2009; 8:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allgaier S, Taylor RD, Brudnaya Y, et al. Vaccine production in Neurospora crassa. Biologicals 2009; 37:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2022-2023. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Ann Allergy Asthma Immunol 2018; 120:49.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2011 report. http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf (Accessed on September 20, 2013).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2389 Version 71.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22608573" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Adverse reactions to vaccines practice parameter 2012 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25428412" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26365388" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523172" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk of anaphylaxis after vaccination of children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527305" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124371" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adverse events associated with intranasal influenza vaccine in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26452420" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of anaphylaxis after vaccination in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19356614" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20060576" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20451987" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Ovalbumin content of influenza vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397313" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ovalbumin content of 2010-2011 influenza vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9821418" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Safe administration of influenza vaccine to patients with egg allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368312" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Safety of influenza vaccine administration in egg-allergic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20579720" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21055666" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The safety of the H1N1 influenza A vaccine in egg allergic individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21094520" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21530882" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Safe administration of seasonal influenza vaccine to children with egg allergy of all severities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21459425" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Single-dose influenza vaccination of patients with egg allergy in a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22236726" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021881" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Egg-allergic patients can be safely vaccinated against influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23176882" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577640" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25684279" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Safety of live attenuated influenza vaccine in atopic children with egg allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26645895" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19673652" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19673651" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19453397" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : FluBlok, a recombinant hemagglutinin influenza vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19348564" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Using plant cells as influenza vaccine substrates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19285427" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Vaccine production in Neurospora crassa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19374929" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Influenza vaccines based on virus-like particles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868284" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21329971" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36065750" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34448800" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29273128" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
